Lone Star Bio

Found 17,106 articles

• 

  BioSpace Launches 2022 Hotbed Maps to Highlight Thriving Life Sciences Clusters

  1/18/2022

  As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.

• Baylor Genetics Announces Neuromuscular Disorders Panel

  5/22/2023

  Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing and precision medicine, announced the availability of a Neuromuscular Disorders Panel.

• Castle Biosciences Opens New State-of-the-Art Laboratory in Pittsburgh

  5/22/2023

  Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, announced that it has opened a new state-of-the-art laboratory facility in Pittsburgh.

• Lumos Pharma to Participate in World Orphan Drug Congress USA

  5/22/2023

  Lumos Pharma, Inc., a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency through Phase 2 clinical trials, announced that management will participate in panel discussions at the World Orphan Drug Congress USA 2023, held in Washington, D.C., May 23-25, 2023.

• bioAffinity Technologies Presents Research Findings at CYTO 2023

  5/22/2023

  bioAffinity Technologies, Inc. today will present the poster “Development of porphyrin-stained polystyrene compensation beads for use on an automated analysis platform” at CYTO 2023 , the annual Congress for the International Society for the Advancement of Cytometry (ISAC), in Montréal, Québec, Canada.

• FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsXBiotech Believes its Drug Candidate Natrunix Could Revolutionize Arthritis Treatment

  5/22/2023

  XBiotech Inc. (NASDAQ: XBIT) today reports that the FDA’s Division of Rheumatology has authorized the Company to initiate a Phase II clinical study to test Natrunix™ as a treatment for Rheumatoid Arthritis.

• 7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding

  5/22/2023

  7 Hills Pharma LLC announced that it has been awarded $13.5MM in nondilutive grant funds from the Cancer Prevention & Research Institute of Texas to advance 7HP349, its first-in-class oral selective integrin activator into a Phase 1b/2a clinical trial in patients who are resistant to PD-1-based therapies.

• Coya to Present Additional Biomarker and Brain Imaging Data for COYA 301 in Alzheimer’s Disease (AD) at the LD Micro Conference on June 7, 2023

  5/22/2023

  Coya previously announced results from an open-label study of COYA 301 in 8 patients with Alzheimer’s disease (AD) that resulted in a statistically significant improvement in cognitive function, as measured by the Mini-Mental State Examination test (MMSE).

• Nanoscope Therapeutics Announces Presentations at the World Orphan Drug Congress

  5/22/2023

  Nanoscope Therapeutics Inc. today announced that its Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in multiple presentations at the World Orphan Drug Congress, taking place May 23-25, 2023.

• Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules - May 19, 2023

  5/19/2023

  Forte Biosciences, Inc., a biopharmaceutical company focused on autoimmune diseases, announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.

• Taysha Gene Therapies Presents Preclinical Data on TSHA-102 for Rett Syndrome Demonstrating Cellular Regulation of MeCP2 Expression in Key Mouse Models at the American Society of Gene and Cell Therapy 26th Annual Meeting

  5/19/2023

  Taysha Gene Therapies today presents preclinical data from neonatal mouse models on TSHA-102 for Rett syndrome, including new data in wild-type mice, at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting.

• Monogram Orthopaedics Shares Begin Trading Publicly on NASDAQ

  5/18/2023

  Monogram Orthopedics announced it raised $17,216,147 is pleased to announce that its common stock will begin trading on the NASDAQ, May 18, 2023, at approximately 11:00 am EST under the ticker symbol "MGRM."

• Colossal Biosciences and the Vertebrate Genomes Project Publish the First Near Complete African Elephant Chromosome Level Genome

  5/18/2023

  Colossal Biosciences, a breakthrough biosciences and genetic engineering company, and the Vertebrate Genomes Project, which aims to sequence high-quality reference genomes for all living vertebrates, partnered to successfully generate the first high-quality reference genome of the African elephant.

• Paradromics Raises $33 Million in Funding, Achieves Breakthrough Medical Device Designation from FDA

  5/18/2023

  Paradromics Inc., the leading developer of high data-rate brain-computer interfaces (BCI), today announced a $33 million Series A funding round led by Prime Movers Lab.

• Perimeter Medical Imaging AI Announces Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Corporate Update

  5/18/2023

  Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a commercial-stage medical technology company – announced it will report its first quarter 2023 financial and operating results after the close of U.S. financial markets on Thursday, May 25, 2023.

• XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares

  5/17/2023

  Xbiotech Inc. announced that it commenced a “modified Dutch auction” issuer tender offer to purchase up to $80,000,000 in value of its common shares, or such lesser number of common shares as are properly tendered and not properly withdrawn, at a price not greater than $4.00 nor less than $3.80 per common share, to the seller in cash, less any applicable withholding taxes and without interest.

• Monogram Orthopaedics Announces Closing of Public Offering of $17,216,147

  5/17/2023

  Monogram Orthopaedics Inc. announced it raised $17,216,147 through the sale of 2,374,641 shares of its Class A Common Stock priced at $7.25 per share.

• Indapta Therapeutics Announces U.S. FDA Clearance of IND for IDP-023, an Allogeneic Natural Killer (NK) Cell Therapy for Cancer

  5/17/2023

  Indapta Therapeutics, Inc. today announced that the company has reached agreement with the U.S. Food and Drug Administration (FDA) on an Investigational New Drug (IND) application to commence its first-in-human phase 1 trial in patients with multiple myeloma and lymphoma anticipated to begin in the second half of 2023.

• Lantern Pharma to Present at the Lytham Partners Spring 2023 Investor Conference Thursday, May 18th at 9:00 a.m. ET

  5/17/2023

  Lantern Pharma to Present at the Lytham Partners Spring 2023 Investor Conference Thursday, May 18th at 9:00 a.m. ET.

• Coya Therapeutics’ COYA 301 Increased Treg Function and Halted Cognitive Decline in an Open Label Study in Patients with Alzheimer’s Disease

  5/16/2023

  Coya Therapeutics, Inc. today reported results from an open-label proof-of-concept clinical study for COYA 301 in patients with AD.